KM

Kuppuswamy Manivannan

Director DIN 02500537
DIN 02500537 First appointment Mar 2009
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Mar 2009
Shareholding value β€’β€’β€’β€’ Premium profile

About Kuppuswamy Manivannan

Data last updated:

Kuppuswamy Manivannan was a Director at Unicordis Pharma India Private Limited (from 2013) and Director at Rhythm Pharma India Private Limited (from 2009).

DIN 02500537
First Appointment 23 Mar 2009
Oldest Company Age 17 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director23 Apr 20132013₹17.3 Lakh (FY 2016)Strike Off
Rhythm Pharma India Private Limited U51397TZ2009PTC015095
Director23 Mar 20092009₹1.39 Cr (FY 2016)Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Unicordis Pharma India Private Limited
Rhythm Pharma India Private Limited
Premium access

Shareholding and investment profile for Kuppuswamy Manivannan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kuppuswamy Manivannan

Kuppuswamy Manivannan was first appointed on 23 Mar 2009 as Director at Rhythm Pharma India Private Limited. The most recent appointment on record is 23 Apr 2013 at Unicordis Pharma India Private Limited.

Kuppuswamy Manivannan held 2 earlier board appointments: Unicordis Pharma India Private Limited (Director, from 23 Apr 2013); Rhythm Pharma India Private Limited (Director, from 23 Mar 2009).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available